CRITICAL ISSUES OF PAPILLOMA VIRUS INFECTION PREVENTION
Abstract
The article details the issue of malignancy caused by human papilloma virus (HPV), as well as characteristics of this virus. Its genetic stability allows for efficient prevention of this pathology through vaccination. 2 vaccines, which are approved by the FDA end EMEA for use and are registered in Russia, have been created and are successfully used for this purpose. The authors believe that the best results may be achieved by combining screening examination programmes with universal reasonable administration of scheduled voluntary vaccination of Russia’s population.
Key words: human papilloma virus, HPV infection, cervical cancer, malignancies, prevention, vaccination.
Key words: human papilloma virus, HPV infection, cervical cancer, malignancies, prevention, vaccination.
About the Authors
E.V. Uvarova
V.I. Kulakov Federal State Institute Research Centre of Obstetrics, Gynecology and Perinatology of Russia’s Agency of Healthcare and Social Development
Russian Federation
Russian Federation
Z.Kh. Kumykova
V.I. Kulakov Federal State Institute Research Centre of Obstetrics, Gynecology and Perinatology of Russia’s Agency of Healthcare and Social Development
Russian Federation
Russian Federation
Review
For citations:
Uvarova E., Kumykova Z. CRITICAL ISSUES OF PAPILLOMA VIRUS INFECTION PREVENTION. Pediatric pharmacology. 2011;8(1):17-21.
Views:
465
Email this article 